Clinical trial
A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
NCT04943900 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 9, 2021
- Completion date
- February 27, 2025
- Enrollment
- 67 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors